Fingerprint
Dive into the research topics of 'Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph Drabick, Montaser F. Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses Sadek, Lucinda L. Tennant, Christopher M. Smith, Eugene P. Kennedy, Charles J. Link, Nicholas N. Vahanian, Jiayi Yu, Steven S. Shen, Erik L. Brincks, Gabriela R. Rossi, David Munn, Mohammed Milhem
Research output: Contribution to journal › Article › peer-review
39
Scopus
citations